Physician profile
John Robertson
NPI 1881858215
$5,711.23
in general payments reported to CMS, 2019-2025
45 companies · $619 in 2025
The $619 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,046 · 2020: $411 · 2021: $1,022 · 2022: $1,075 · 2023: $858 · 2024: $680 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,156.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,359.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $441.29 | 2019-2025 | |
| Abbvie INC. | $400.02 | 2021-2025 | Vraylar, Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $365.08 | 2019-2025 | Xifaxan |
| Neurocrine Biosciences, INC. | $322.28 | 2019-2023 | Ingrezza |
| Glaxosmithkline, LLC. | $225.89 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Alkermes, INC. | $183.08 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $171.05 | 2023-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $159.06 | 2019-2022 | |
| Abiomed | $137.65 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.62 | 2019-2022 | |
| Astellas Pharma US INC | $125.06 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $117.51 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $113.81 | 2020-2025 | Breztri, Airsupra |
| Amarin Pharma, INC. | $103.14 | 2019-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Robertson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.